Overview

An Exploratory Study of MT-2990 in Patients With AAV

Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.
Phase:
Phase 1
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation